Skip to main content

Table 3 Prediction of time to end of treatment (TTOT) in patients not progressing under letrozole

From: Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study

 

Possible predictors

Hazard Ratio

95% Confidence Interval

p-value

Lower Bound

Upper Bound

Competing Risk Regression Model 1

Age (in years)

1.02

0.97

1.08

0.373

BMI (kg/m2)

1.02

0.94

1.11

0.563

Number of concomitant medications

0.63

0.33

1.19

0.155

ECOG

0.52

0.07

4,07

0.532

Time from diagnosis to therapy (in years)

0.96

0.84

1.10

0.565

Adverse events within the first 30 days

8.24

3.02

22.49

< 0.0001

Competing Risk Regression Model 2

Do you sometimes forget to take your medicine?

0.81

0.20

3.24

0.762

Do you take all your medicine always at the same time?

1.15

0.23

5.68

0.864

Do you sometimes not take your medicine if you feel good?

0.72

0.26

1.96

0.523

Do you not take your medicine at all if you feel worse due to illness?

4.00

1.89

8.44

0.0003

On how many days in the past 30 days did you not take/forget to take your medicine?

2.79

1.30

6.00

0.008

How satisfied were you with the information provided regarding endocrine treatment and its side effects?

0.84

0.18

3.86

0.818